OBJECTIVE: The aim of the study was to describe the clinical presentation and prognosis in HIV-1-infected patients with hospital admission and pandemic influenza A 2009 (H1N1) confirmed, and compare this data with those of a general population. DESIGN: : This is a prospective study in nature. METHODS: All adult patients admitted to 13 hospitals in Spain with confirmed influenza A 2009(H1N1) virus infection by real-time reverse transcriptase PCR assay or culture from June 12 to November 10, 2009 were recruited and followed up until 1 month after discharge. In the HIV group risk factors for HIV infection, AIDS criteria, last CD4 cell count and viral load, and antiretroviral therapy and pneumococcal vaccines were collected. RESULTS: Five hundred and eighty-five patients were recruited, 26 with HIV-1 infection and 559 non-HIV. The HIV patients had a long-term well controlled infection with a median CD4 cell count 503 cells/μl and 84% with undetectable viral load, although more frequently they had chronic liver and chronic obstructive pulmonary disease. No significant differences were observed about reported symptoms and physical findings on hospital admission. About 50% of patients in both groups present radiological infiltrates and 30% present respiratory failures. Practically all the patients in both groups received influenza antiviral therapy and in each group 80% received antibacterial therapy. No differences were observed in clinical outcomes. CONCLUSION: In HIV patients, well controlled on HAART, the pandemic influenza virus AH1N1 had a similar clinical outcome and prognosis to that of non-HIV patients.
OBJECTIVE: The aim of the study was to describe the clinical presentation and prognosis in HIV-1-infectedpatients with hospital admission and pandemic influenza A 2009 (H1N1) confirmed, and compare this data with those of a general population. DESIGN: : This is a prospective study in nature. METHODS: All adult patients admitted to 13 hospitals in Spain with confirmed influenza A 2009(H1N1) virus infection by real-time reverse transcriptase PCR assay or culture from June 12 to November 10, 2009 were recruited and followed up until 1 month after discharge. In the HIV group risk factors for HIV infection, AIDS criteria, last CD4 cell count and viral load, and antiretroviral therapy and pneumococcal vaccines were collected. RESULTS: Five hundred and eighty-five patients were recruited, 26 with HIV-1 infection and 559 non-HIV. The HIV patients had a long-term well controlled infection with a median CD4 cell count 503 cells/μl and 84% with undetectable viral load, although more frequently they had chronic liver and chronic obstructive pulmonary disease. No significant differences were observed about reported symptoms and physical findings on hospital admission. About 50% of patients in both groups present radiological infiltrates and 30% present respiratory failures. Practically all the patients in both groups received influenza antiviral therapy and in each group 80% received antibacterial therapy. No differences were observed in clinical outcomes. CONCLUSION: In HIV patients, well controlled on HAART, the pandemic influenza virus AH1N1 had a similar clinical outcome and prognosis to that of non-HIV patients.
Authors: Nancy F Crum-Cianflone; Erik Iverson; Gabriel Defang; Patrick J Blair; Lynn E Eberly; Jason Maguire; Anuradha Ganesan; Dennis Faix; Christopher Duplessis; Tahaniyat Lalani; Timothy Whitman; Carolyn Brandt; Grace Macalino; Eugene V Millar; Timothy Burgess Journal: Vaccine Date: 2011-03-01 Impact factor: 3.641
Authors: Ignacio Martin-Loeches; Emili Díaz; Loreto Vidaur; Antoni Torres; Cesar Laborda; Rosa Granada; Juan Bonastre; Mar Martín; Josu Insausti; Angel Arenzana; Jose Eugenio Guerrero; Ines Navarrete; Jesus Bermejo-Martin; David Suarez; Alejandro Rodriguez Journal: Crit Care Date: 2011-11-28 Impact factor: 9.097
Authors: Ana M Balanzat; Christian Hertlein; Carlos Apezteguia; Pablo Bonvehi; Luis Cámera; Angela Gentile; Oscar Rizzo; Manuel Gómez-Carrillo; Fatima Coronado; Eduardo Azziz-Baumgartner; Pollyanna R Chávez; Marc-Alain Widdowson Journal: PLoS One Date: 2012-04-10 Impact factor: 3.240
Authors: Claire-Anne Siegrist; Christian van Delden; Michael Bel; Christophe Combescure; Cécile Delhumeau; Matthias Cavassini; Olivier Clerc; Sara Meier; Karine Hadaya; Paola M Soccal; Sabine Yerly; Laurent Kaiser; Bernard Hirschel; Alexandra Calmy Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240
Authors: James M Trauer; Don Bandaranayake; Robert Booy; Mark I Chen; Michelle Cretikos; Gary K Dowse; Dominic E Dwyer; Michael E Greenberg; Q Sue Huang; Gulam Khandaker; Jen Kok; Karen L Laurie; Vernon J Lee; Jodie McVernon; Scott Walter; Peter G Markey Journal: Emerg Infect Dis Date: 2013-01 Impact factor: 6.883
Authors: Timothy R Leahy; Michelle Goode; Paul Lynam; Patrick J Gavin; Karina M Butler Journal: Influenza Other Respir Viruses Date: 2014-02-18 Impact factor: 4.380